Comparative In Vitro Release of Eletriptan Hydrobromide Formulations for Buccal Administration
Makaleler > Tam Makale · 2024
Yazarlar: Sinem Yaprak KARAVANA, Meliha GÜNEŞ, simge ararat
DISSOLUTION TECHNOLOGIES, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2024, cilt 31, ss 190-194
Özet
<p>Introduction: Migraine is a neurological disease characterized by unilateral headache attacks that can last between 4-72 hours and accompanying different symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, or movement sensitivity. Eletriptan hydrobromide (EHBR) has been recognized as a reliable and efficient treatment for severe to moderate migraine attacks, with or without aura. Buccal drug administration is the most preferred route of administration compared to other alternative routes of administration. Orally disintegrating tablets (ODT), orally disintegrating films (ODF), and in situ gel systems are popular dosage forms that can be used without the need for chewing or water when the medication is taken. With these features, they create important advantages for patients with dysphagia or problems with water intake. Methods: ODT, ODF, and in situ gel formulations were developed and evaluated in terms of dissolution profiles. Results: For the ODT formulation, more than 85% of the EHBR dissolved within the first 15 minutes. For the ODF formulation, 78% cumulative release was observed in the first 15-minutes. At the end of 4 hours, 93% cumulative drug release of EHBR from in situ gel was observed. Conclusion: Based on the results of these dissolution studies, ODT and ODF formulations for treatment of acute migraine attacks provide a rapid effect</p>